Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 December 2018Website:
http://www.modernatx.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 7 min agoDividend
Analysts recommendations
Institutional Ownership
MRNA Latest News
The mRNA technology that helped create COVID-19 vaccines quickly is now leading to significant changes in medicine. Berenberg suggests that this new method could change how we treat various illnesses, especially cancer and infectious diseases.
Last week, shares of some major vaccine companies in Europe and the U.S. dropped after Robert F. Kennedy Jr. was nominated to head the Department of Health and Human Services.
Jim Cramer from CNBC shares the most recent updates about Moderna.
Moderna, Inc. (NASDAQ:MRNA) will be participating in Guggenheim's first Healthcare Innovation Conference on November 12, 2024, at 10:00 AM ET. The company will be represented by Stephen Hoge, the President. Evan Wang, a senior biotech analyst at Guggenheim, will also be part of the conference.
Stock prices for some of the biggest drug companies in the U.S. dropped yesterday after President-elect Donald Trump chose Robert F. Kennedy Jr. to be the secretary of the Department of Health and Human Services (HHS).
Shares of vaccine companies like Moderna, Pfizer, and Novavax dropped significantly just before the market closed on Thursday. This decline followed news that President-elect Donald Trump might choose Robert F. Kennedy Jr., who is known for his skepticism about vaccines, to lead the Department of Health and Human Services.
On Thursday, shares of companies that produce vaccines dropped after it was announced that President-elect Donald Trump had chosen Robert F. Kennedy Jr., a known vaccine skeptic and former presidential candidate, to head the U.S. Department of Health and Human Services.
EMERYVILLE, Calif.--(BUSINESS WIRE)--CRDMO offers specialized services for various mRNA uses, such as producing small amounts for personalized cancer vaccines (PCVs).
On Thursday, Moderna Inc. MRNA announced that its revenue for the third quarter was $1.83 billion, which is higher than the expected $1.25 billion.
mRESVIA is Moderna's second product approved in Canada and is the first mRNA vaccine for RSV, available in single-dose pre-filled syringes. Canada is the fourth region to approve mRESVIA, following the U.S., Europe, and Qatar. Stéphane Bancel, CEO of Moderna, stated that this approval highlights the potential of mRNA technology to tackle major public health issues like RSV, especially for older adults.
What type of business is Moderna?
Moderna, Inc. is an American biotechnology company focused on the development of drugs and vaccines based on messenger RNA (mRNA). The company was founded in 2010, with its headquarters located in Cambridge, Massachusetts. Moderna, Inc. has built a platform for the identification and development of new drugs based on mRNA. The platform is based on accumulated knowledge and continuous advancements in the field of fundamental and applied mRNA science, mRNA delivery to target tissues, and manufacturing processes for producing potential mRNA-based drugs.
What sector is Moderna in?
Moderna is in the Healthcare sector
What industry is Moderna in?
Moderna is in the Biotechnology industry
What country is Moderna from?
Moderna is headquartered in United States
When did Moderna go public?
Moderna initial public offering (IPO) was on 07 December 2018
What is Moderna website?
https://www.modernatx.com
Is Moderna in the S&P 500?
Yes, Moderna is included in the S&P 500 index
Is Moderna in the NASDAQ 100?
Yes, Moderna is included in the NASDAQ 100 index
Is Moderna in the Dow Jones?
No, Moderna is not included in the Dow Jones index
When was Moderna the previous earnings report?
No data
When does Moderna earnings report?
The next expected earnings date for Moderna is 21 February 2025